present a vaginal gel that was effective to prevent the spread of AIDS
was effective up to 54% of women in a study that was done in Africa.
For
Sibila Camps A vaginal spermicide gel has shown an average 39% effective in preventing the spread of the AIDS virus, and 54% in women who used it more often. The trial, conducted by the Center for AIDS Research Program in South Africa (CAPRISA, its acronym in English) was presented at the XVIII International AIDS Conference, which is taking place in Vienna.
Women are more vulnerable to HIV infection, anatomical and biological reasons, but also cultural. Gender inequalities mean that many can not negotiate that monogamy is mutual, or that their partner use a condom during sex.
For that reason, women's organizations have been demanding for many years the development of a female contraceptive that serves as a barrier against the AIDS virus, so that the decision to care-of pregnancy and infection, is in hands of them.
The first trial of a vaginal gel of its kind, two years ago, showed no positive effects. Now the CAPRISA gel developed by the drug tenofovir, showed encouraging results. Tested for 30 months in 445 sexually active women, compared with other 444 who used a placebo, showed that women who used less than half of sexual contacts and in which they applied between 50 and 80% of the time, the average women who were not infected with the virus was 28% and 38% respectively. In women using the gel more than 80% of their relations, the efficacy was 54%.
"While not everything we had expected, is 39% more than what we had before," said Mabel Bianco, president of FEIM and coordinator of the International Group for Women and AIDS. The doctor urged Argentina to continue to improve the effectiveness of microbicides, while warning that should not abandon the current prevention measures.
was effective up to 54% of women in a study that was done in Africa.
For
Sibila Camps A vaginal spermicide gel has shown an average 39% effective in preventing the spread of the AIDS virus, and 54% in women who used it more often. The trial, conducted by the Center for AIDS Research Program in South Africa (CAPRISA, its acronym in English) was presented at the XVIII International AIDS Conference, which is taking place in Vienna.
Women are more vulnerable to HIV infection, anatomical and biological reasons, but also cultural. Gender inequalities mean that many can not negotiate that monogamy is mutual, or that their partner use a condom during sex.
For that reason, women's organizations have been demanding for many years the development of a female contraceptive that serves as a barrier against the AIDS virus, so that the decision to care-of pregnancy and infection, is in hands of them.
The first trial of a vaginal gel of its kind, two years ago, showed no positive effects. Now the CAPRISA gel developed by the drug tenofovir, showed encouraging results. Tested for 30 months in 445 sexually active women, compared with other 444 who used a placebo, showed that women who used less than half of sexual contacts and in which they applied between 50 and 80% of the time, the average women who were not infected with the virus was 28% and 38% respectively. In women using the gel more than 80% of their relations, the efficacy was 54%.
"While not everything we had expected, is 39% more than what we had before," said Mabel Bianco, president of FEIM and coordinator of the International Group for Women and AIDS. The doctor urged Argentina to continue to improve the effectiveness of microbicides, while warning that should not abandon the current prevention measures.
0 comments:
Post a Comment